|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM193183951 |
| 003 |
DE-627 |
| 005 |
20250211014135.0 |
| 007 |
tu |
| 008 |
231223s2009 xx ||||| 00| ||chi c |
| 028 |
5 |
2 |
|a pubmed25n0644.xml
|
| 035 |
|
|
|a (DE-627)NLM193183951
|
| 035 |
|
|
|a (NLM)19951496
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a chi
|
| 100 |
1 |
|
|a Wang, Shu-chun
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Prognostic factors of immunosuppressive therapy in children acquired aplastic anemia
|
| 264 |
|
1 |
|c 2009
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 02.12.2010
|
| 500 |
|
|
|a Date Revised 03.12.2021
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a OBJECTIVE: To investigate prognostic factors of immunosuppressive therapy (IST) in children acquired severe aplastic anemia(SAA)
|
| 520 |
|
|
|a METHODS: Data of 56 consecutive children cases with SAA who had received rabbit anti-thymocyte globulin (R-ATG) [3-5 mg/( kg x d) x 5 d] and cyclosporine A (CSA) from January 2000 to June 2006 were retrospectively analyzed. No repeated courses of R-ATG were given for nonresponders. All the patients also received stanozolol or testosterone propionate. The dose of CSA was adjusted to maintain trough drug levels above 100 microg/L and peak drug levels above 300 microg/L
|
| 520 |
|
|
|a RESULTS: The overall response rate to the immunosuppressive therapy (IST) was 62.5% and the complete remission rate was 37.5%. The 5-year overall survival for IST regimens was 66.27% +/- 6.84%, patients who had infections when using ATG had significantly lower response and higher mortality. Patients whose nucleated erythrocyte population in bone marrow was > or =10% had good prognosis. Patients whose granulocytes population in bone marrow was > or =10% had lower mortality
|
| 520 |
|
|
|a CONCLUSION: Patients who had infections when using ATG had significantly lower response and higher mortality. Patients whose nucleated erythrocyte population in bone marrow was > or =10% had good prognosis
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Antilymphocyte Serum
|2 NLM
|
| 650 |
|
7 |
|a Immunosuppressive Agents
|2 NLM
|
| 650 |
|
7 |
|a Cyclosporine
|2 NLM
|
| 650 |
|
7 |
|a 83HN0GTJ6D
|2 NLM
|
| 700 |
1 |
|
|a Chen, Xiao-juan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zou, Yao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, Wen-yu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Tian-feng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Li
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Yu-mei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Guo, Ye
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhu, Xiao-fan
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Zhonghua er ke za zhi = Chinese journal of pediatrics
|d 1960
|g 47(2009), 8 vom: 02. Aug., Seite 613-6
|w (DE-627)NLM136249191
|x 0578-1310
|7 nnns
|
| 773 |
1 |
8 |
|g volume:47
|g year:2009
|g number:8
|g day:02
|g month:08
|g pages:613-6
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_50
|
| 912 |
|
|
|a GBV_ILN_61
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_227
|
| 912 |
|
|
|a GBV_ILN_244
|
| 912 |
|
|
|a GBV_ILN_285
|
| 912 |
|
|
|a GBV_ILN_294
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_665
|
| 912 |
|
|
|a GBV_ILN_813
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 47
|j 2009
|e 8
|b 02
|c 08
|h 613-6
|